Clinical safety of biosimilar recombinant human granulocyte colony-stimulating factors

Ivo L Abraham, Soba Tharmarajah, Karen Macdonald

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Introduction: A 'biosimilar', or 'similar biological medicinal product', is a biologic agent that is similar in terms of quality, safety and efficacy to an authorized reference biological medicine. Since the expiration of the filgrastim patent in Europe, three agents have received marketing authorization from the EMA: Tevagrastim, Zarzio and Nivestim. Tevagrastim has also been approved as a biologic by the FDA as tbo-filgrastim. Areas covered: Using the EMA dossiers (all three agents), the FDA dossier (Tevagrastim), and journal publications, this article reviews clinical safety data for these products with emphasis on serious/severe adverse events and special consideration of immunogenicity, bone pain, splenomegaly, allergic reactions, acute respiratory distress syndrome and mortality. Expert opinion: All three agents have similar safety profiles. None were statistically higher on safety parameters to what is known about originator filgrastim (Neupogen). What is known about filgrastim in general regarding safety can be extended to biosimilar filgrastim. Safety profiles may become more differentiated once long-term product-specific safety data are available. Large-sample, long-term, observational studies of real-world practice will provide the heterogeneity and statistical power to demonstrate product-specific safety profiles. Current evidence indicates that statistically no one product is less and no one product is more safe.

Original languageEnglish (US)
Pages (from-to)235-246
Number of pages12
JournalExpert Opinion on Drug Safety
Volume12
Issue number2
DOIs
StatePublished - Mar 2013

Fingerprint

Biosimilar Pharmaceuticals
Granulocyte Colony-Stimulating Factor
Safety
Splenomegaly
Adult Respiratory Distress Syndrome
Expert Testimony
Biological Factors
Anniversaries and Special Events
Marketing
Observational Studies
Publications
Filgrastim

Keywords

  • Biosimilar pharmaceuticals
  • Biosimilars
  • Drug safety
  • Granulocyte colony-stimulating factor
  • Recombinant proteins
  • Safety

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Clinical safety of biosimilar recombinant human granulocyte colony-stimulating factors. / Abraham, Ivo L; Tharmarajah, Soba; Macdonald, Karen.

In: Expert Opinion on Drug Safety, Vol. 12, No. 2, 03.2013, p. 235-246.

Research output: Contribution to journalArticle

Abraham, Ivo L ; Tharmarajah, Soba ; Macdonald, Karen. / Clinical safety of biosimilar recombinant human granulocyte colony-stimulating factors. In: Expert Opinion on Drug Safety. 2013 ; Vol. 12, No. 2. pp. 235-246.
@article{5f8fa02f1c9f4c07bc700f9a03057dc2,
title = "Clinical safety of biosimilar recombinant human granulocyte colony-stimulating factors",
abstract = "Introduction: A 'biosimilar', or 'similar biological medicinal product', is a biologic agent that is similar in terms of quality, safety and efficacy to an authorized reference biological medicine. Since the expiration of the filgrastim patent in Europe, three agents have received marketing authorization from the EMA: Tevagrastim, Zarzio and Nivestim. Tevagrastim has also been approved as a biologic by the FDA as tbo-filgrastim. Areas covered: Using the EMA dossiers (all three agents), the FDA dossier (Tevagrastim), and journal publications, this article reviews clinical safety data for these products with emphasis on serious/severe adverse events and special consideration of immunogenicity, bone pain, splenomegaly, allergic reactions, acute respiratory distress syndrome and mortality. Expert opinion: All three agents have similar safety profiles. None were statistically higher on safety parameters to what is known about originator filgrastim (Neupogen). What is known about filgrastim in general regarding safety can be extended to biosimilar filgrastim. Safety profiles may become more differentiated once long-term product-specific safety data are available. Large-sample, long-term, observational studies of real-world practice will provide the heterogeneity and statistical power to demonstrate product-specific safety profiles. Current evidence indicates that statistically no one product is less and no one product is more safe.",
keywords = "Biosimilar pharmaceuticals, Biosimilars, Drug safety, Granulocyte colony-stimulating factor, Recombinant proteins, Safety",
author = "Abraham, {Ivo L} and Soba Tharmarajah and Karen Macdonald",
year = "2013",
month = "3",
doi = "10.1517/14740338.2013.770472",
language = "English (US)",
volume = "12",
pages = "235--246",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Clinical safety of biosimilar recombinant human granulocyte colony-stimulating factors

AU - Abraham, Ivo L

AU - Tharmarajah, Soba

AU - Macdonald, Karen

PY - 2013/3

Y1 - 2013/3

N2 - Introduction: A 'biosimilar', or 'similar biological medicinal product', is a biologic agent that is similar in terms of quality, safety and efficacy to an authorized reference biological medicine. Since the expiration of the filgrastim patent in Europe, three agents have received marketing authorization from the EMA: Tevagrastim, Zarzio and Nivestim. Tevagrastim has also been approved as a biologic by the FDA as tbo-filgrastim. Areas covered: Using the EMA dossiers (all three agents), the FDA dossier (Tevagrastim), and journal publications, this article reviews clinical safety data for these products with emphasis on serious/severe adverse events and special consideration of immunogenicity, bone pain, splenomegaly, allergic reactions, acute respiratory distress syndrome and mortality. Expert opinion: All three agents have similar safety profiles. None were statistically higher on safety parameters to what is known about originator filgrastim (Neupogen). What is known about filgrastim in general regarding safety can be extended to biosimilar filgrastim. Safety profiles may become more differentiated once long-term product-specific safety data are available. Large-sample, long-term, observational studies of real-world practice will provide the heterogeneity and statistical power to demonstrate product-specific safety profiles. Current evidence indicates that statistically no one product is less and no one product is more safe.

AB - Introduction: A 'biosimilar', or 'similar biological medicinal product', is a biologic agent that is similar in terms of quality, safety and efficacy to an authorized reference biological medicine. Since the expiration of the filgrastim patent in Europe, three agents have received marketing authorization from the EMA: Tevagrastim, Zarzio and Nivestim. Tevagrastim has also been approved as a biologic by the FDA as tbo-filgrastim. Areas covered: Using the EMA dossiers (all three agents), the FDA dossier (Tevagrastim), and journal publications, this article reviews clinical safety data for these products with emphasis on serious/severe adverse events and special consideration of immunogenicity, bone pain, splenomegaly, allergic reactions, acute respiratory distress syndrome and mortality. Expert opinion: All three agents have similar safety profiles. None were statistically higher on safety parameters to what is known about originator filgrastim (Neupogen). What is known about filgrastim in general regarding safety can be extended to biosimilar filgrastim. Safety profiles may become more differentiated once long-term product-specific safety data are available. Large-sample, long-term, observational studies of real-world practice will provide the heterogeneity and statistical power to demonstrate product-specific safety profiles. Current evidence indicates that statistically no one product is less and no one product is more safe.

KW - Biosimilar pharmaceuticals

KW - Biosimilars

KW - Drug safety

KW - Granulocyte colony-stimulating factor

KW - Recombinant proteins

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=84874121792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874121792&partnerID=8YFLogxK

U2 - 10.1517/14740338.2013.770472

DO - 10.1517/14740338.2013.770472

M3 - Article

C2 - 23419039

AN - SCOPUS:84874121792

VL - 12

SP - 235

EP - 246

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - 2

ER -